Antifibrinolytic Therapy for Cardiac Surgery: An Update

Anesthesiology. 2015 Jul;123(1):214-21. doi: 10.1097/ALN.0000000000000688.

Authors

Andreas Koster¹, David Faraoni, Jerrold H Levy

Affiliation

¹ From the Institute for Anesthesiology, Heart and Diabetes Centre North-Rheine Westphalia, Bad Oeynhausen, Ruhr-University Bochum, Bochum, Germany (A.K.); Department of Anesthesiology, Perioperative and Pain Medicine, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts (D.F.); and Department of Anesthesiology and Intensive Care, Duke University School for Medicine, Durham, North Carolina (J.H.L.).

PMID: 25950230
DOI: 10.1097/ALN.0000000000000688

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Antifibrinolytic Agents / administration & dosage*
Aprotinin / administration & dosage
Blood Loss, Surgical / prevention & control*
Cardiac Surgical Procedures / adverse effects*
Cardiac Surgical Procedures / trends
Clinical Trials as Topic / trends
Humans

Substances

Antifibrinolytic Agents
Aprotinin